Neuroscience and psychiatry
The present evolution in clinical psychiatry with respect to schizophrenia focuses on the early detection of individuals who are at risk of developing the disease, since experience shows that the prognosis is much more favourable if treatment starts early. It is therefore essential to identify biological markers, which are currently lacking, in order to specify whether a person is vulnerable to schizophrenia; it is also crucial to develop new molecules likely to avoid the unfolding of the pathology (prevention) or to impede its harmful progression once it has broken out (treatment). These are the objectives of the Unit for Research in Schizophrenia (URS), which strives to bridge clinical issues with basic research, and works along the following lines:
- The collection of biological and psychological observations in patients;
- The investigation of disease mechanisms in experimental models;
- The exploration of biological markers and innovative, potentially preventive treatments.
Presentation of the translational research program supported by the Alamaya Foundation. The video was shot for APA TV (American Psychiatric Association) and broadcasted at the Annual Meeting of the Association, in May 2014, in New York (USA).
Interview with Prof. Kim Do Cuénod at the 29th ECNP Congress (European College of Neuropsychopharmacology) – September 2016 – Vienna (Austria)
Plenary lecture of Prof. Kim Do Cuénod at the 29th ECNP Congress (European College of Neuropsychopharmacology) – September 2016 – Vienna (Austria)
Virtual Event Neuroscience – Kim Do Cuénod was invited to participate in a webinar organized by LabRoots, leader in the field of scientific networking – March 2015
Inaugural Lesson of Prof. Kim Do Cuénod, Tuesday April 8th, 2014, Lausanne University Hospital, Switzerland (French only):
Neurosciences et psychiatrie : le développement du cerveau, toutes les chances et tous les risques